141 related articles for article (PubMed ID: 27737881)
1. Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.
Liu Y; Pandeswara S; Dao V; Padrón Á; Drerup JM; Lao S; Liu A; Hurez V; Curiel TJ
Cancer Res; 2017 Jan; 77(2):520-531. PubMed ID: 27737881
[TBL] [Abstract][Full Text] [Related]
2. Comparative methodologies of regulatory T cell depletion in a murine melanoma model.
Matsushita N; Pilon-Thomas SA; Martin LM; Riker AI
J Immunol Methods; 2008 Apr; 333(1-2):167-79. PubMed ID: 18295790
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication.
Chaoul N; Fayolle C; Desrues B; Oberkampf M; Tang A; Ladant D; Leclerc C
Cancer Res; 2015 Aug; 75(16):3279-91. PubMed ID: 26122844
[TBL] [Abstract][Full Text] [Related]
5. IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer.
Thibodeaux SR; Barnett BB; Pandeswara S; Wall SR; Hurez V; Dao V; Sun L; Daniel BJ; Brumlik MJ; Drerup J; Padrón Á; Whiteside T; Kryczek I; Zou W; Curiel TJ
Clin Cancer Res; 2021 Jul; 27(13):3661-3673. PubMed ID: 33771857
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).
Atchison E; Eklund J; Martone B; Wang L; Gidron A; Macvicar G; Rademaker A; Goolsby C; Marszalek L; Kozlowski J; Smith N; Kuzel TM
J Immunother; 2010 Sep; 33(7):716-22. PubMed ID: 20664355
[TBL] [Abstract][Full Text] [Related]
7. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
[TBL] [Abstract][Full Text] [Related]
9. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
Vallera DA; Taylor PA; Aukerman SL; Blazar BR
Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
[TBL] [Abstract][Full Text] [Related]
10. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
[TBL] [Abstract][Full Text] [Related]
11. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
[TBL] [Abstract][Full Text] [Related]
12. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.
Hurez V; Daniel BJ; Sun L; Liu AJ; Ludwig SM; Kious MJ; Thibodeaux SR; Pandeswara S; Murthy K; Livi CB; Wall S; Brumlik MJ; Shin T; Zhang B; Curiel TJ
Cancer Res; 2012 Apr; 72(8):2089-99. PubMed ID: 22496463
[TBL] [Abstract][Full Text] [Related]
13. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.
Svatek RS; Ji N; de Leon E; Mukherjee NZ; Kabra A; Hurez V; Nicolas M; Michalek JE; Javors M; Wheeler K; Sharp ZD; Livi CB; Shu ZJ; Henkes D; Curiel TJ
Cancer Immunol Res; 2019 Mar; 7(3):466-475. PubMed ID: 30563829
[TBL] [Abstract][Full Text] [Related]
15. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.
Brunn GJ; Williams J; Sabers C; Wiederrecht G; Lawrence JC; Abraham RT
EMBO J; 1996 Oct; 15(19):5256-67. PubMed ID: 8895571
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin inhibits the growth of glioblastoma.
Arcella A; Biagioni F; Antonietta Oliva M; Bucci D; Frati A; Esposito V; Cantore G; Giangaspero F; Fornai F
Brain Res; 2013 Feb; 1495():37-51. PubMed ID: 23261661
[TBL] [Abstract][Full Text] [Related]
17. Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.
Zhang Y; Hua C; Cheng H; Wang W; Hao S; Xu J; Wang X; Gao Y; Zhu X; Cheng T; Yuan W
Leuk Res; 2013 Nov; 37(11):1592-601. PubMed ID: 24090996
[TBL] [Abstract][Full Text] [Related]
18. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
[TBL] [Abstract][Full Text] [Related]
19. Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro.
Trendowski M; Christen TD; Andonova AA; Narampanawe B; Thibaud A; Kusang T; Fondy TP
Invest New Drugs; 2015 Dec; 33(6):1162-74. PubMed ID: 26490657
[TBL] [Abstract][Full Text] [Related]
20. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice.
Krawczyk CM; Verstovsek S; Ujházy P; Maccubbin D; Ehrke MJ
Cancer Immunol Immunother; 1995 Jun; 40(6):347-57. PubMed ID: 7627991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
